

ACT Sheet

Newborn Screening ACT Sheet

[Elevated C3-DC Acylcarnitine]

Malonic Acidemia

Differential Diagnosis: None.

Condition Description: Malonic acidemia is caused by deficiency of malonyl-CoA decarboxylase, which disrupts the regulation of fatty acid synthesis and breakdown and leads to elevated malonic acid and malonylcarnitine (C3-DC). This disorder has a variable phenotype and may present during the neonatal period through adulthood.

You Should Take the Following <u>IMMEDIATE</u> Actions:

- Inform family of the newborn screening result.
- Ascertain clinical status (poor feeding, lethargy, seizures).
- Consult with pediatric metabolic specialist the same day.
- Evaluate the newborn (poor feeding, respiratory distress, lethargy, seizures, hypoglycemia). If any of these findings are present or if the newborn is ill, transport to a hospital for further treatment in consultation with the metabolic specialist.
- Initiate confirmatory/diagnostic testing as recommended by the specialist.
- Provide family with basic information about malonic acidemia and its management.
- Report final diagnostic outcome to newborn screening program.

Diagnostic Evaluation: Plasma acylcarnitines: C3-DC is elevated in malonic acidemia. Urine organic acids demonstrate elevated malonic acid. Molecular genetic testing can confirm the diagnosis.

Clinical Considerations: Malonic acidemia can present acutely in the neonatal period with respiratory distress, seizures, hypoglycemia, metabolic acidosis and lethargy. More commonly, malonic acidemia presents during infancy or later childhood with developmental delay, seizures, failure to thrive, hypotonia, hypoglycemia, metabolic acidosis, and cardiomyopathy. Treatment is supportive and directed at promoting normal growth and development.

Additional Information:

How to Communicate Newborn Screening Results

Emergency Protocols (New England Consortium of Metabolic Programs)

Gene Reviews

Medline Plus

Condition Information for Families- HRSA Newborn Screening Clearinghouse

Referral (local, state, regional, and national):

Find a Genetics Clinic Directory
Genetic Testing Registry

This practice resource is designed primarily as an educational resource for medical geneticists and other clinicians to help them provide quality medical services. Adherence to this practice resource is completely voluntary and does not necessarily assure a successful medical outcome. This practice resource should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the clinician should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen. Clinicians are encouraged to document the reasons for the use of a particular procedure or test, whether or not it is in conformance with this practice resource. Clinicians also are advised to take notice of the date this practice resource was adopted, and to consider other medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures.



ACT Sheet

[Elevated C3-DC Acylcarnitine]
Malonic Acidemia

State and Other Resources

State Newborn Screening Program

Metabolic (Bloodspot) Screening, Montana's Newborn Screening Programs 406-444-0984, dphhs.mt.gov/ecfsd/cshs/newbornscreeningprograms/

Short-term Follow-up Coordinator - Crystal Fortune, MT Laboratory Services Bureau 406-444-0930 or 800-821-7284 cfortune@mt.gov

Genetics/Metabolics Consultants

Shodair Children's Hospital Medical Genetics Staff will contact you with recommendations. Metabolic Clinic: 406-444-1099; Clinics held across Montana: 406-444-1016 shodair.org/about-shodair/contact/

If emergency consultation with a metabolic specialist is necessary, contact One Call (24/7) at Children's Hospital Colorado (800-525-4871) and ask to speak to the metabolic specialist on call.

Information for Clinicians and Families

Montana Medical Home Portal (see Newborn Disorders and Parents & Families sections) mt.medicalhomeportal.org/newborn/malonic-acidemia

Parent/Family Support

Organic Acidemia Association www.oaanews.org/ma.html

National Resources (with web addresses)

Additional Information

How to Communicate Newborn Screening Results

www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/Resources/achdnc-communication-guide-newborn.pdf

Emergency Protocols (New England Consortium of Metabolic Programs) www.newenglandconsortium.org/methyl

Gene Reviews

www.ncbi.nlm.nih.gov/books/NBK1231/

Medline Plus

medlineplus.gov/genetics/condition/malonyl-coa-decarboxylase-deficiency/

Condition Information for Families-HRSA Newborn Screening Clearinghouse newbornscreening.hrsa.gov/conditions/malonyl-coa-decarboxylase-deficiency

Referral (local, state, regional and national)

Find a Genetics Clinic Directory clinics.acmg.net

Genetic Testing Registry www.ncbi.nlm.nih.gov/gtr/

This practice resource is designed primarily as an educational resource for medical geneticists and other clinicians to help them provide quality medical services. Adherence to this practice resource is completely voluntary and does not necessarily assure a successful medical outcome. This practice resource should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the clinician should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen. Clinicians are encouraged to document the reasons for the use of a particular procedure or test, whether or not it is in conformance with this practice resource. Clinicians also are advised to take notice of the date this practice resource was adopted, and to consider other medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures.